
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.

Policy· June 4, 2026 · 13 min read
By Ran Chen#GLP-1#Medicare Part D#Payer Coverage

Pricing & Access· May 31, 2026 · 15 min read
Biomarker documentation mismatch in oncology prior authorization
By Ran Chen#Oncology#Prior Authorization#Payer Policy

Pricing & Access· May 31, 2026 · 12 min read
Biosimilar HCPCS and NDC crosswalk errors that deny claims
By Ran Chen#Biosimilars#HCPCS Coding#Payer Coverage

Specialty· May 31, 2026 · 12 min read
Cold-chain excursion workflow for specialty pharmacy replacement drug

Pricing & Access· May 31, 2026 · 12 min read
Companion diagnostic denial before oncology drug prior authorization

Pricing & Access· May 31, 2026 · 14 min read
Switching from compounded GLP-1s to FDA-approved therapy
By Ran Chen#GLP-1#FDA Approval#Market Access

Pricing & Access· May 31, 2026 · 13 min read
Electronic prior authorization readiness for specialty drugs in 2027
By Ran Chen#Prior Authorization#CMS#Specialty Drugs

Pricing & Access· May 31, 2026 · 13 min read
FHIR prior authorization fields that cause specialty-drug denials
By Ran Chen#Prior Authorization#CMS#Specialty Drugs

Pricing & Access· May 31, 2026 · 12 min read
GLP-1 appeal evidence after cardiometabolic comorbidity denial
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs

Pricing & Access· May 31, 2026 · 13 min read
GLP-1 reauthorization after BMI drops below the original threshold
By Ran Chen#GLP-1#Prior Authorization#Medicare Part D